Zevra Therapeutics, Inc. ZVRA Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s accounts payable and other current liabilities (note 11)?
- Zevra Therapeutics, Inc. (ZVRA) reported accounts payable and other current liabilities (note 11) of $11.69M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s accounts payable and other current liabilities (note 11) changed year-over-year?
- Zevra Therapeutics, Inc.'s accounts payable and other current liabilities (note 11) decreased by 34.4% year-over-year, from $17.82M to $11.69M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accounts payable and other current liabilities (note 11) has grown at a 11.8% compound annual growth rate (CAGR), from $6.65M to $11.6M.